<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04571944</url>
  </required_header>
  <id_info>
    <org_study_id>4305-085</org_study_id>
    <secondary_id>MK-4305-085</secondary_id>
    <secondary_id>jRCT2031200149</secondary_id>
    <nct_id>NCT04571944</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085)</brief_title>
  <official_title>A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of MK-4305 (Suvorexant) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the efficacy and safety of suvorexant (MK-4305) for&#xD;
      reducing the incidence of delirium in Japanese participants who are at high risk of delirium.&#xD;
      The primary hypothesis is that suvorexant reduces the proportion of participants with&#xD;
      delirium compared with placebo as assessed by the diagnostic and statistical manual of mental&#xD;
      disorders 5th edition (DSM-5) criteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2020</start_date>
  <completion_date type="Anticipated">March 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 4, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with delirium as assessed by diagnostic and statistical manual of mental disorders 5th edition (DSM-5) criteria</measure>
    <time_frame>Up to ~8 days</time_frame>
    <description>DSM-5 is the gold standard for diagnosis of delirium. DSM-5 criteria will be used for clinician assessment of delirium. The percentage of participants with delirium per DSM-5 criteria will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience one or more adverse events (AEs)</measure>
    <time_frame>Up to ~21 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who discontinue study treatment due to an AE</measure>
    <time_frame>Up to ~7 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum daily total score on Delirium Rating Scale-Revised-98 (DRS-R-98)</measure>
    <time_frame>Up to ~8 days</time_frame>
    <description>DRS-R-98 is a diagnostic and assessment tool used for evaluation of delirium. It is a 16-item clinician-rated scale with 13 items measuring delirium severity and 3 diagnostic items. The total DRS-R-98 score can range from 0 (lowest) to 46 (highest). Higher scores indicate worsening or more severe delirium. The maximum daily total score on DRS-R-98 will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with delirium as assessed by DRS-R-98</measure>
    <time_frame>Up to ~8 days</time_frame>
    <description>DRS-R-98 is a diagnostic and assessment tool used for evaluation of delirium. It is a 16-item clinician-rated scale with 13 items measuring delirium severity and 3 diagnostic items. The total DRS-R-98 score can range from 0 (lowest) to 46 (highest). Higher scores indicate worsening or more severe delirium. Optimized cutoff score for delirium diagnosis in Japanese translated DRS-R-98 has been determined as ≥14.5. The percentage of participants with delirium as assessed by DRS-R-98, defined as the percentage of participants with total score ≥14.5 per DRS-R-98, will be presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Delirium</condition>
  <arm_group>
    <arm_group_label>Suvorexant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 15 mg of suvorexant orally once daily (QD) for 5 to 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive suvorexant-matching placebo orally QD for 5 to 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suvorexant</intervention_name>
    <description>Suvorexant administered at a dose of 15 mg QD via oral tablet</description>
    <arm_group_label>Suvorexant</arm_group_label>
    <other_name>MK-4305</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Suvorexant-matching placebo administered QD via oral tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is hospitalized for (1) acute disease with severe disease state or decreased daily&#xD;
             living function or (2) elective surgery requiring general anesthesia scheduled on the&#xD;
             day after or 2 days after admission/Day 1&#xD;
&#xD;
          -  Has (1) mild cognitive impairment or mild dementia and/or (2) a history of delirium in&#xD;
             any prior hospitalization&#xD;
&#xD;
          -  Requires hospitalization for 6 days for acute disease, with treatment starting on day&#xD;
             of admission; or 7 days, with treatment starting the day after admission OR&#xD;
&#xD;
          -  Requires hospitalization for 6 days for elective surgery scheduled on the day after&#xD;
             admission; or for 7 days for elective surgery scheduled 2 days after admission&#xD;
&#xD;
          -  Is able to take study medications orally&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has moderate or severe dementia&#xD;
&#xD;
          -  Has a history of epilepsy or Parkinson's disease&#xD;
&#xD;
          -  Currently uses psychotropic agents or has a mental condition including schizophrenia,&#xD;
             other mental disorders, bipolar disorder and major depression&#xD;
&#xD;
          -  Has a history of drug or alcohol abuse in the 5 years prior to start of study or has&#xD;
             alcoholic disease such as alcoholic liver disease or gastritis alcoholic&#xD;
&#xD;
          -  Has a history of narcolepsy or cataplexy&#xD;
&#xD;
          -  Has used hypnotics, antipsychotics, mood stabilizers, antidepressants, anxiolytics,&#xD;
             psychostimulants, anticonvulsants or tiapride within 2 weeks prior to randomization&#xD;
&#xD;
          -  Has delirium as assessed by DSM-5 or DRS-R-98 (total score ≥14.5) before the first&#xD;
             dose of study medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kohnodai Hospital, National Center for Global Health and Medicine ( Site 8522)</name>
      <address>
        <city>Ichikawa</city>
        <state>Chiba</state>
        <zip>272-8516</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Iizuka Hospital ( Site 8540)</name>
      <address>
        <city>Iizuka</city>
        <state>Fukuoka</state>
        <zip>820-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-948-22-3800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital ( Site 8537)</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>802-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-93-511-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maebashi Red Cross Hospital ( Site 8548)</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <zip>371-0811</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-27-265-3333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fukuyama City Hospital ( Site 8528)</name>
      <address>
        <city>Fukuyama</city>
        <state>Hiroshima</state>
        <zip>721-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-84-941-5151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tonan Hospital ( Site 8512)</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-11-231-2121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansai Rosai Hospital ( Site 8550)</name>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <zip>660-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-6-6416-1221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanazawa Medical University Hospital ( Site 8514)</name>
      <address>
        <city>Kahoku-gun</city>
        <state>Ishikawa</state>
        <zip>920-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Kagawa University Hospital ( Site 8519)</name>
      <address>
        <city>Kita-gun</city>
        <state>Kagawa</state>
        <zip>761-0793</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-87-898-5111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>TAKAMATSU Red Cross Hospital ( Site 8547)</name>
      <address>
        <city>Takamatsu</city>
        <state>Kagawa</state>
        <zip>760-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-87-831-7101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Musashi Kosugi Hospital ( Site 8502)</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>211-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-44-733-5181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Showa University Northern Yokohama Hospital ( Site 8534)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>224-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-45-949-7000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Medical Center ( Site 8516)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-45-261-5656</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohamashi Nanbu Hospital ( Site 8541)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>234-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-45-832-1111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Hospital ( Site 8515)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-45-787-2800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Yokohama Medical Center ( Site 8531)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>245-8575</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-45-851-2621</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Maizuru Medical Center ( Site 8535)</name>
      <address>
        <city>Maizuru-shi</city>
        <state>Kyoto</state>
        <zip>625-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-773-62-2680</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aizawa Hospital ( Site 8542)</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <zip>390-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-263-33-8600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital ( Site 8524)</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-6-6879-5111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toyonaka Municipal Hospital ( Site 8521)</name>
      <address>
        <city>Toyonaka</city>
        <state>Osaka</state>
        <zip>560-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-6-6843-0101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shimane Prefectural Central Hospital ( Site 8530)</name>
      <address>
        <city>Izumo</city>
        <state>Shimane</state>
        <zip>693-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-8-5322-5111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kamitsuga General Hospital ( Site 8546)</name>
      <address>
        <city>Kanuma</city>
        <state>Tochigi</state>
        <zip>322-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-289-64-2161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SANO KOSEI GENERAL HOSPITAL ( Site 8551)</name>
      <address>
        <city>Sano</city>
        <state>Tochigi</state>
        <zip>327-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-283-22-5222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital ( Site 8525)</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-285-44-2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University Hospital ( Site 8517)</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <zip>755-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-836-22-2111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Medical Center ( Site 8532)</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-92-852-0700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hiroshima City Hiroshima Citizens Hospital ( Site 8505)</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-8518</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-82-221-2291</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kumamoto Medical Center ( Site 8511)</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-96-353-6501</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Kyoto Daini Hospital ( Site 8533)</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8026</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-75-231-5171</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyoto Katsura Hospital ( Site 8539)</name>
      <address>
        <city>Kyoto</city>
        <zip>615-8256</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>＋81-75-391-5811</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miyazaki Prefectural Miyazaki Hospital ( Site 8543)</name>
      <address>
        <city>Miyazaki</city>
        <zip>880-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-985-24-4181</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niigata City General Hospital ( Site 8544)</name>
      <address>
        <city>Niigata</city>
        <zip>950-1197</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-25-281-5151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Okayama Saiseikai General Hospital ( Site 8549)</name>
      <address>
        <city>Okayama</city>
        <zip>700-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-86-252-2211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital ( Site 8510)</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-86-223-7151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka City General Hospital ( Site 8518)</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-6-6929-1221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka National Hospital ( Site 8536)</name>
      <address>
        <city>Osaka</city>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-6-6942-1331</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Osaka Hospital ( Site 8523)</name>
      <address>
        <city>Osaka</city>
        <zip>543-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-6-6774-5111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Japan Community Health care Organization Osaka Hospital ( Site 8545)</name>
      <address>
        <city>Osaka</city>
        <zip>553-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-6-6441-5451</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka General Medical Center ( Site 8538)</name>
      <address>
        <city>Osaka</city>
        <zip>558-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-6-6692-1201</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saga-Ken Medical Centre Koseikan ( Site 8526)</name>
      <address>
        <city>Saga</city>
        <zip>840-8571</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-952-24-2171</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokushima Prefectural Central Hospital ( Site 8509)</name>
      <address>
        <city>Tokushima</city>
        <zip>770-8539</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-88-631-7151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital ( Site 8520)</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3542-2511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical and Dental University Hospital ( Site 8503)</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3813-6111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Tokyo Medical Center ( Site 8529)</name>
      <address>
        <city>Tokyo</city>
        <zip>152-8902</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3411-0111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital ( Site 8527)</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-3353-8111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juntendo University Nerima Hospital ( Site 8501)</name>
      <address>
        <city>Tokyo</city>
        <zip>177-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81-3-5923-3111</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

